Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database

Table 4 Adjusted annual indirect costs ($) due to short-term disabilities by type of comorbidity

Comorbidity	No. of patients with comorbidity	Adjusted costs for patients with comorbidity	No. of patients without comorbidity	Adjusted costs for patients without comorbidity	Incremental adjusted costs	Lower 95% CL	Upper 95% CL
Psoriatic arthritis	516	1346.7	5362	860.0	403.5	−44.9	852.0
Cardiovascular disease	543	1635.0	5335	828.2	817.8	314.1	1321.6
Depression	355	2112.7	5523	825.0	996.6	431.6	1561.6
Anxiety	267	1344.2	5611	881.8	267.8	−300.9	832.8
Diabetes	570	1816.3	5308	804.7	928.0	400.1	1456.0
Hyperlipidemia	1624	1163.2	4254	803.3	356.5	70.0	643.0
Hypertension	1373	1319.0	4505	775.9	576.5	233.7	919.3
Obesity	189	2293.4	5689	856.6	1195.1	16.1	2374.1
Cerebrovascular disease	81	2501.5	5797	880.4	1333.1	−181.1	2847.2
Peripheral vascular disease	64	1912.2	5814	891.6	994.9	−789.2	2779.0
Any of the above^a	3123	1191.9	2755	575.0	614.1	390.0	838.2

Note: The adjusted costs were predicted based on the model results using the recycled prediction method [38] for patients with and without comorbidities using the study sample. The incremental adjusted costs are differences in the adjusted costs between patients with and without comorbidities. The 95% CLs were calculated using bootstrapping method for both direct and indirect costs
^aAny of the above comorbidities means if patients have any of the either comorbidities mentioned above

ISSN: 1472-6963